Clustering data with hclust algorithm for (Study ST002126)
(Analysis AN003479)| Metabolite | Structure | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| [13C]Malate | ME516732 | 5.46 | 0.00 | 0.00 | 0.00 | 2.50 | NA | NA | 0.01 | 0.01 | 0.01 |
| [13C]Citrate | ME516730 | 4.97 | 0.03 | 0.03 | 0.03 | 2.74 | NA | NA | 0.05 | 0.09 | 0.07 |
| [13C]Succinate | ME516733 | 4.84 | 0.00 | 0.00 | 0.00 | 3.13 | NA | NA | 0.00 | 0.01 | 0.01 |
| [13C]Alpha_Ketoglutarate | ME516729 | 4.80 | 0.00 | 0.01 | 0.00 | 3.15 | NA | NA | 0.01 | 0.01 | 0.01 |
| [13C]Fumatate | ME516731 | 4.77 | 0.01 | 0.01 | 0.01 | 3.15 | NA | NA | 0.01 | 0.03 | 0.02 |
| [13C, 15N]Methionine, 2TBDMS | ME516722 | 0.30 | 2.67 | 0.82 | 1.45 | 0.23 | NA | 0.26 | 2.42 | 0.14 | 0.71 |
| [13C, 15N]Histidine, 3TBDMS | ME516718 | 0.29 | 2.65 | 0.73 | 1.51 | 0.24 | NA | 0.27 | 2.67 | 0.15 | 0.49 |
| [13C, 15N]Proline, 2TBDMS | ME516724 | 0.24 | 2.69 | 0.77 | 1.29 | 0.15 | NA | 0.27 | 2.72 | 0.19 | 0.69 |
| [13C, 15N]Tyrosine, 3TBDMS | ME516727 | 0.34 | 2.77 | 0.68 | 1.26 | 0.21 | NA | 0.34 | 2.61 | 0.16 | 0.64 |
| [13C, 15N]Phenylalanine, 2TBDMS | ME516723 | 0.15 | 2.42 | 1.14 | 1.39 | 0.13 | NA | 0.16 | 2.68 | 0.28 | 0.64 |
| [13C, 15N]Threonine, 3TBDMS | ME516726 | 0.07 | 2.57 | 1.04 | 1.49 | 0.05 | NA | 0.08 | 2.56 | 0.29 | 0.85 |
| [13C, 15N]Valine, 2TBDMS | ME516728 | 0.02 | 2.52 | 1.06 | 1.62 | 0.02 | NA | 0.02 | 2.65 | 0.30 | 0.79 |
| [13C, 15N]Glutamic acid, 3TBDMS | ME516716 | 0.32 | 2.34 | 0.90 | 1.59 | 0.14 | NA | 0.29 | 2.47 | 0.16 | 0.79 |
| [13C, 15N]Isoleucine, 2TBDMS | ME516719 | 0.15 | 2.45 | 1.08 | 1.72 | 0.12 | NA | 0.13 | 2.52 | 0.21 | 0.62 |
| [13C, 15N]Lysine, 3TBDMS | ME516721 | 0.17 | 2.64 | 1.02 | 1.68 | 0.12 | NA | 0.21 | 2.47 | 0.09 | 0.60 |
| [13C, 15N]Serine, 3TBDMS | ME516725 | 0.11 | 2.67 | 0.72 | 1.80 | 0.07 | NA | 0.15 | 2.65 | 0.14 | 0.69 |
| [13C, 15N]Alanine, 2TBDMS | ME516714 | 0.07 | 2.71 | 0.82 | 1.42 | 0.06 | NA | 0.06 | 3.01 | 0.16 | 0.70 |
| [13C, 15N]Leucine, 2TBDMS | ME516720 | 0.18 | 2.37 | 0.78 | 1.55 | 0.12 | NA | 0.17 | 2.84 | 0.20 | 0.80 |
| [13C, 15N]Aspartic acid, 3TBDMS | ME516715 | 0.40 | 2.28 | 1.12 | 1.46 | 0.28 | NA | 0.29 | 2.09 | 0.34 | 0.74 |
| [13C, 15N]Glycine, 2TBDMS | ME516717 | 0.03 | 2.30 | 1.24 | 1.53 | 0.02 | NA | 0.02 | 2.27 | 0.58 | 1.00 |
Factors:
| F1 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). |
| F2 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). |
| F3 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). |
| F4 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). |
| F5 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J). |
| F6 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). |
| F7 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J). |
| F8 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). |
| F9 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). |
| F10 | Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L). |
